Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the renal cell carcinoma drug market will more than double over the next 10 years, rising from $625 million in 2007 to nearly $1.6 billion in 2017. Market growth will continue to be driven by the dominance of the multikinase inhibitors drug class, most notably Pfizer's Sutent.

According to the new Pharmacor report entitled Renal Cell Carcinoma, Sutent will maintain its position as the leading therapy for the disease and will capture $841 million in sales in 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The report finds that multikinase inhibitors, which comprised 92 percent of the renal cell carcinoma drug market in 2007, will capture nearly three quarters of the market in 2017.

The report also finds that three emerging targeted therapies- GlaxoSmithKline's Armala, Pfizer's axitinib and Novartis's everolimus-will launch over the next decade and will achieve significant uptake in the second- line patient segment through 2017. Additionally, although there are no treatments that have, to date, shown efficacy in the adjuvant setting in nonmetastatic renal cell carcinoma patients, the results of clinical trials underway in this patient segment could further drive market growth.

"The most notable trial currently underway, the Adjuvant Sorafenib or Sunitinib in Unfavorable Renal Cell Carcinoma trial, is comparing the efficacy of Sutent versus Bayer Healthcare/Onyx's Nexavar versus placebo in extending disease-free survival in the adjuvant setting," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "If these drugs are approved for treatment in the adjuvant setting, their use in this setting will be a major driver of growth in the renal cell carcinoma market over the next decade."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Potential Blues Merger Poses Concern for Area Health Systems

View Now